Woodcock: COVID Is Not The Time For Structural Changes At US FDA

Acting FDA Commissioner Janet Woodcock says FDA is interested in establishing new ‘Centers of Excellence’ but the current environment is not the right time to make changes at the agency. Woodcock also talked about where FDA will spend its new pandemic money and its reexamination of accelerated approval drugs in a wide-sweeping conversation with the Alliance for a Stronger FDA.

Janet Woodcock speaks at Alliance for a Stronger FDA
FDA Acting Commissioner Janet Woodcock speaks at the Alliance for a Stronger FDA on 14 April. • Source: Screenshot

More from US FDA

More from Agency Leadership